TrialAdvances in therapy2022

Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.

Leslie Citrome et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.